PMID- 16938570
OWN - NLM
STAT- MEDLINE
DCOM- 20061030
LR  - 20161124
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 169
IP  - 2
DP  - 2006 Sep
TI  - Interphase FISH analysis of PTEN in histologic sections shows genomic deletions 
      in 68% of primary prostate cancer and 23% of high-grade prostatic 
      intra-epithelial neoplasias.
PG  - 128-37
AB  - Prostate cancer (CaP) is characterized by the accumulation of both genetic and 
      epigenetic alterations that transform premalignant lesions to invasive carcinoma. 
      However, the molecular events underlying this critical transition are poorly 
      understood. One of the important genes that might play a role in CaP development 
      is the PTEN gene. At the present time, there has been no systematic analysis of 
      the incidence of genomic PTEN deletion by fluorescence in situ hybridization 
      (FISH) in CaP and associated preneoplastic histologic lesions. This study 
      assesses the frequency of PTEN deletion by interphase FISH analysis in CaP and 
      prostatic intra-epithelial neoplasia (PIN). Dual-color FISH was performed using 
      DNA probes for bands 10q23.3 (PTEN locus) and chromosome 10 centromere using 35 
      radical prostatectomy specimens. PTEN deletions were not found in 3/3 of stroma, 
      6/6 samples of benign glandular epithelium, and 12/12 samples of low-grade PIN. 
      However, PTEN deletions were found in 3/13 (23%) of high-grade PIN and 24/35 
      (68%) of CaP. Concordance was observed between PTEN deletion status and the 
      overall cellular PTEN protein expression levels, as assessed by 
      immunohistochemistry. The high frequency of PTEN deletion observed in CaP versus 
      precursor lesions implicates a pivotal role for PTEN haploinsufficiency in the 
      transition from preneoplastic PIN to CaP. Moreover, this observation is an 
      important consideration for novel therapeutic trials in CaP in which biologic 
      efficacy is influenced by the activity level of PTEN. These findings draw 
      attention to the usefulness of this relatively simple FISH assay for future 
      applications in clinical laboratories.
FAU - Yoshimoto, Maisa
AU  - Yoshimoto M
AD  - Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, 
      Toronto, 610 University Ave., Room 9-721, Toronto, Ontario, M5G 2M9 Canada.
FAU - Cutz, Jean-Claude
AU  - Cutz JC
FAU - Nuin, Paulo A S
AU  - Nuin PA
FAU - Joshua, Anthony M
AU  - Joshua AM
FAU - Bayani, Jane
AU  - Bayani J
FAU - Evans, Andrew J
AU  - Evans AJ
FAU - Zielenska, Maria
AU  - Zielenska M
FAU - Squire, Jeremy A
AU  - Squire JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Gene Deletion
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Male
MH  - PTEN Phosphohydrolase/*genetics
MH  - Prostatectomy
MH  - Prostatic Intraepithelial Neoplasia/*genetics
MH  - Prostatic Neoplasms/*genetics
EDAT- 2006/08/30 09:00
MHDA- 2006/10/31 09:00
CRDT- 2006/08/30 09:00
PHST- 2006/02/21 00:00 [received]
PHST- 2006/04/06 00:00 [accepted]
PHST- 2006/08/30 09:00 [pubmed]
PHST- 2006/10/31 09:00 [medline]
PHST- 2006/08/30 09:00 [entrez]
AID - S0165-4608(06)00252-4 [pii]
AID - 10.1016/j.cancergencyto.2006.04.003 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2006 Sep;169(2):128-37. doi: 
      10.1016/j.cancergencyto.2006.04.003.